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Abstract. Sulfadoxine/pyrimethamine (SP) is increasingly used against malaria in sub-Saharan Africa because of
chloroquine resistance. However, chloroquine may have a beneficial antipyretic effect. We therefore compared the
combination of SP plus chloroquine, chloroquine alone, SP alone, and SP plus paracetamol in the treatment of uncom-
plicated Plasmodium falciparum malaria in 175 Tanzanian children (1−4 years old) in a randomized trial. Outcome
variables were axillary temperatures every six hours, daily parasitemias, and serum levels of IgG antibodies to P.
falciparum. Lower mean temperatures (6−48 hours) were achieved with SP plus chloroquine or paracetamol than with
SP alone (P < 0.001) or chloroquine alone (P < 0.05). All three SP-treated groups showed high and similar parasite
reduction (0−48 hours), whereas treatment with chloroquine alone was much less effective. Levels of IgG antibodies to
P. falciparum increased significantly (P < 0.001) and similarly in the four treatment groups between days 0, 2. and 3.
Thus, the addition of chloroquine or paracetamol to SP improved the clinical outcome, but did not affect the parasi-
tologic response or antibody production.
INTRODUCTION
Despite partial resistance of Plasmodium falciparum to
chloroquine in sub-Saharan Africa, malaria is still commonly
treated with this drug because it is inexpensive and well tol-
erated. Sulfadoxine/pyrimethamine (SP) is usually the next
choice for treatment when chloroquine is no longer used, as it
is also affordable, rarely associated with severe side effects,
and can be given in a single dose.1,2 Several African coun-
tries, mainly in eastern Africa, have introduced SP as a first-
line treatment. Tanzania has done so recently, but at the time
of the present study, chloroquine was still the first-line treat-
ment. Some countries are now also considering combination
treatment to increase efficacy and potentially reduce or pre-
vent the evolution of resistance to the drugs used.
Despite better parasitologic response after treatment with
SP, when compared with chloroquine, the clinical responses
may be less rapid.3 An optimal treatment regimen may there-
fore be to combine SP and chloroquine, thus optimizing both
the anti-parasitic and clinical effects.
Two earlier studies have compared the clinical efficacy of
SP versus SP plus chloroquine. No significant difference in
fever clearance time was reported by Darlow and others,4
while Bojang and others had a significantly higher number of
patients returning to the clinic because of persistent fever or
other clinical symptoms in the SP alone group.5 No significant
difference in parasite reduction was observed between the
treatment groups in these studies.4,5 A faster resolution of
clinical symptoms during chloroquine treatment may be ex-
plained by its anti-inflammatory properties. In vitro, chloro-
quine inhibits the production of several pro-inflammatory cy-
tokines, believed to contribute to the pathogenesis and clini-
cal manifestations of malaria infection and rheumatoid
arthritis, diseases commonly treated with chloroquine.6−12
However, the anti-inflammatory effects of chloroquine may
also potentially interfere with natural anti-parasitic immune
responses.
Paracetamol is a commonly used antipyretic in children and
is often combined with SP. However, paracetamol and other
antipyretics have been recommended to be used with caution
during P. falciparum malaria because of alleged poor anti-
pyretic effects and delayed parasite clearance.13,14
We wanted to conduct a more comprehensive study than
those previously performed, including more frequent record-
ing of temperature and correlating the anti-parasitic effect
directly with the antipyretic effect of chloroquine. We also
wanted to study a possible effect on the humoral immune
response by chloroquine and paracetamol elicited by infec-
tion with P. falciparum.
This study was therefore designed to compare four treat-
ment regimens all presently in use in Africa, i.e., SP alone, SP
in combination with either chloroquine or paracetamol, and
chloroquine alone. The outcome variables were fever, para-
sitemia, and production of IgG towards crude P. falciparum
antigens.
METHODS
Study area. The study was conducted in the Kibaha Dis-
trict Hospital 40 km northwest of Dar es Salaam, Tanzania.
The area is holoendemic for malaria with largely perennial
transmission of mainly P. falciparum.
Study patients. Children between 12 and 59 months of age
attending the primary health care unit of the hospital between
July 3 and August 20, 1998 were included in the study if they
had uncomplicated mono-infection with P. falciparum, a
parasite density of 2,000−250,000 parasites/L, an axillary
temperature of 37.5–40.0°C, no history of drug intake in the
last two weeks, and no history of hypersensitivity drug reac-
tions. Children were not eligible for the study if they had
severe malaria as defined by altered level of consciousness,
convulsions, prostration, circulatory shock or respiratory dis-
tress, hyperparasitemia (> 250,000 parasites/L), or severe
anemia (hemoglobin level < 50 g/L). Children with signs of
coexisting diseases were also excluded. The guardians of the
children satisfying the inclusion criteria were asked for their
informed consent for the children to be enrolled into the
study. Ethical clearance was obtained from the Ministry of
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Health of Tanzania and the clinical research committee of the
Karolinska Institutet (Stockholm, Sweden).
Drug administration. The patients were given serial num-
bers when attending the primary health care unit, before
screening of parasitemia and fever. When admitted to the
hospital they were consecutively divided into either of four
treatment groups according to a predetermined schedule: 1)
chloroquine alone, 2) SP alone, 3) SP plus chloroquine and 4)
SP plus paracetamol. More patients were allocated to the
group receiving chloroquine alone to balance the two groups
receiving SP alone and SP plus paracetamol. Therefore, on
each day of enrollment it was decided by a toss of a coin if an
additional category 5 for chloroquine alone would be added
in the schedule preceding category 1. The treating physician
was not involved in allocating unique identification numbers
to the patients deciding the order of admittance into the
study. When following the treatment schedule, he could
therefore not influence which patient would be allocated to
each treatment group. The three drugs were given as follows:
1) chloroquine phosphate (F. Hoffman-La Roche, Basel,
Switzerland), 10 + 10 + 5 mg base/kg of body weight over a
period of three days; 2) Fansidar® (F. Hoffman-La Roche), a
single dose of 1.25 mg of pyrimethamine and 25 mg of sulfa-
doxine/kg of body weight; and 3) paracetamol, 15 mg/kg of
body weight every eight hours for 72 hours. The children and
their guardians were not told what treatment arm they were
in. To equalize the number of occasions of tablet intake for
the SP- and chloroquine-treated children, each patient also
received one tablet of vitamin C per day for three days. All
treatments started at 3:00−4:00 PM on the day of admission
and were given under close supervision by the research team.
No antipyretic drugs were given to the children apart from the
treatment schedule defined. Mechanical antipyresis (tepid
sponging and electric fanning) was considered during epi-
sodes of high fever (> 39°C).
Assessment of drug efficacy. The primary outcome in the
study was temperature at 48 hours and the main secondary
outcome was parasite clearance after 72 hours. The children
remained in the ward for three days. Axillary body tempera-
ture was measured with a digital thermometer on admission,
and then every six hours for 72 hours, by the hospital nurses.
Parasite species were assessed by Giemsa-stained thin blood
smears on admission and parasite densities by thick blood
smears daily for four days. The parasite densities were esti-
mated by counting asexual parasites per 200 leukocytes in the
thick smear and expressed as number of parasites per micro-
liter of blood, assuming an average number of 8,000 leuko-
cytes/L of blood. This was performed by a skilled laboratory
assistant. Measures of temperature and counting of parasites
were not influenced by knowledge of which anti-malarial
treatment that was given to the patient. The need for a
double-blinded trial was therefore not considered necessary.
A selected number of the patients in this study were previ-
ously studied for parasite densities and fever survival time.15
Treatment failures. A second-line treatment with quinine
(orally or intravenously) was administered if repeated vom-
iting, signs of clinical deterioration, and/or severe malaria oc-
curred. A second-line treatment with SP was to be given to
children treated with chloroquine alone if 1) the axillary tem-
perature was  37.5°C at 48 hours together with increased
parasitemia compared with day 0, 2) the axillary temperature
was  37.5°C at 72 hours together with detectable parasit-
emia, and 3) the parasitemia at 72 hours was > 25% of the
value at day 0. In case of treatment failure, data from the
patient were included in the analysis up to the time of change
of treatment.
Determination of IgG levels. Blood plasma samples for
analysis of IgG levels were collected at admission and after 48
and 72 hours. Of 169 patients who participated in the study
until 72 hours, 92 were randomly selected for IgG analyses by
drawing of lots within each treatment group. Anti-malarial
IgG levels were determined as previously described.16 Briefly,
enzyme-linked immunosorbent assay plates were coated
with 50 L of Percoll fractionated and lysed parasite cultures
(10 g/mL) per well. The test sera were diluted 1:1,000
and applied in duplicate. Bound IgG was assayed with alka-
line phosphatase−conjugated goat anti-human IgG antibod-
ies (Mabtech, Stockholm, Sweden). Phosphatase sub-
strate (Sigma, St. Louis, MO) was applied and the optical
density was read at 450 nm. The IgG concentrations
were calculated from standard curves obtained by coating
with goat anti-human IgG (Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA), incubating with serial dilu-
tions of recombinant human IgG (Jackson ImmunoResearch
Laboratories, Inc.), and assayed as described earlier in this
report. The detection limit was set on the linear part of the
standard curve and above the background values of buffer
controls.
Statistical analysis. Temperature data were analyzed by
analysis of variance (ANOVA) repeated measurements de-
sign with the independent factors time and treatment. Post
hoc comparisons were performed by planned comparison
with a t-test. The t-test was also used when comparing differ-
ences in temperature between 18 and 24 hours within
each treatment group. The individuals’ mean temperatures
over time (6−24, 30−48, and 6−48 hours) were analyzed by
ANOVA with one independent factor (treatment) at
four levels. Post hoc comparisons were done by the Tukey
test. The mean temperatures of individuals over time
(6−24, 30−48, and 6−48 hours) were also analyzed by mul-
tiple regression and conditional change modeling, adjusting
for initial temperature, parasitemia, age, and sex as co-
variables.
All parasite data were log transformed (loge (x + 1)).
Analyses were performed by ANOVA with one independent
factor (treatment) at four levels with respect to differences in
parasitemia from 0−24 and 0−48 hours. Post hoc pairwise
comparisons were made by the Tukey test. Differences in
parasite reduction from 0−24 and 0−48 hours were also ana-
lyzed using multiple regression and conditional change mod-
eling, adjusting for initial parasitemia, temperature, age, and
sex as co-variables.
The IgG data were log transformed (loge) and differences
between time points (0, 48, and 72 hours) were analyzed using
Wilcoxon matched pairs. Differences in IgG levels between
treatment groups were estimated using multiple linear regres-
sion with log IgG at 48 and 72 hours as dependent variables
and treatment as an independent variable with simultaneous
adjustment for loge IgG time 0, age, sex, and parasitemia time
0. Correlations between changes in temperature and changes
in parasitemia from 0 to 48 hours were estimated by a Spear-
man rank order coefficient. All statistical tests were two sided
with significance levels of 0.05.
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RESULTS
A total of 175 patients were enrolled in the study. The
demographic, clinical, and laboratory data of the four treat-
ment groups are shown in Table 1. All children eventually
recovered, but early treatment failure was recorded in 10 of
them, who therefore had to be treated with a second-line
treatment. Treatment failure was observed in six children af-
ter 48 hours and in another four after 72 hours. Nine children
belonged to the group treated with chloroquine alone,
whereas one child with treatment failure at 48 hours belonged
to the group treated with SP plus chloroquine.
The temperature profiles (0−72 hours) were analyzed by
ANOVA repeated measurements design. Different profiles
were found between children receiving SP alone and all the
other groups, i.e., versus chloroquine (P  0.003), SP plus
chloroquine (P < 0.001), and SP plus paracetamol (P < 0.001).
The mean temperatures during the 0−48-hour time period in
the four treatment groups are shown in Figure 1. After 72
hours of treatment, the mean (minimum-maximun) tempera-
tures were as follows in the four groups: SP alone  36.2°C
(35.5−37.0°C), chloroquine alone 36.3°C (35.1−38.5°C), SP
plus chloroquine  36.2°C (35.6−36.8°C), and SP plus para-
cetamol 36.4°C (35.8−37.2°C). The temperatures increased
temporarily between 18 and 24 hours in each of the two
groups receiving chloroquine given at 0 and 24 hours (P <
0.007, by t-test) (Figure 1). There were no significant differ-
ences between these time points in the other groups.
There was a tendency that SP plus paracetamol gave the
best early reduction in fever from 0 to 6 hours. This reached
statistical significance when compared with SP or chloroquine
alone (P < 0.01), but not when compared with SP plus chlo-
roquine (P  0.3).
The mean temperature during the first day (6−24 hours),
recorded as area under the curve, was highest in the children
treated with SP alone (P < 0.001) (Table 2). As the mean
temperature in the SP alone group started to decrease, the
difference in comparison with the chloroquine alone group
decreased and was not significant during the period of 30−48
hours (P  0.4). Chloroquine alone exhibited similar reduc-
tion in fever as SP plus paracetamol during the first 24 hours
of treatment, but not during the next day (30−48 hours) (P
0.03). Combining chloroquine and SP provided lower tem-
peratures compared with chloroquine alone during both days
(6−24 hours; P  0.03 and 30−48 hours; P < 0.001). No sig-
nificant differences were shown when comparing SP plus
chloroquine with SP plus paracetamol during the two-day pe-
riod. Multiple regression with conditional change modeling
adjusting for age, sex, initial temperature, and parasitemia did
not change the levels of significance in the analyses of mean
temperatures, other than enhancing the differences between
the chloroquine alone group and those treated with SP plus
chloroquine or SP plus paracetamol to P < 0.005 (adjusted
and unadjusted) for all time points except 6−24 hours for SP
plus paracetamol (P  0.03, adjusted and unadjusted). Dif-
ferences in baseline characteristics cannot account for the dif-
ferences seen between the treatment groups.
The effects of the four treatments on parasite prevalences
and densities are shown in Table 3 and Figure 2, respectively.
In the chloroquine-treated group, only half (47%) of the pa-
tients were parasite free after 72 hours compared with 87% in
the three SP-treated groups combined. Similarly, whereas the
median density was reduced from 24,880 to 1,720 parasites/L
after 48 hours in the chloroquine-treated children, the median
parasitemias were below the detection limit in the other three
SP-treated groups. No statistically significant differences in
parasite density reduction (0−48 hours) were found between
any of the three SP-treated groups by multiple regression (P
> 0.09) before and after adjustment for age, sex, initial para-
sitemia, and temperature. Thus, adding chloroquine to SP did
not improve parasite clearance (prevalences or densities).
However, parasite reduction between 0 and 24 hours was
greater in the group treated with SP plus paracetamol com-
pared with any of the other groups by multiple regression (P
< 0.005) before and after adjusting for age, sex, initial para-
sitemia, and temperature.
A weak association (r2  0.2) between decrease in tem-
perature and parasitemia was observed only between 0 and 48
hours in the group treated with chloroquine alone (Figure 3).
The nine patients with significant reduction of parasite load
(> 3,000-fold, i.e., delta log < -8; Figure 3) showed fever re-
duction between 1°C and 4°C. In four of six children with an
increase in parasitemia, fever increased.
Plasma from 92 children randomly selected within the
treatment groups were analyzed for malaria-specific IgG lev-
els. There were general increases in IgG levels by time: day 0
versus day 2, day 2 versus day 3, and day 0 versus 3 (P < 0.001,
by Wilcoxon matched pairs). However, the levels of IgG be-
fore the start of treatment differed somewhat between the
treatment groups (Figure 4). The differences were taken into
account when comparing the IgG levels for the different
treatment groups at days 2 and 3. After adjusting for IgG
levels at day 0, there were no significant differences between
the treatment groups in IgG levels on days 2 or 3.
DISCUSSION
The relatively high rate of early treatment failure within
three days (9 of 56, 16%) confirms a relatively high degree of
TABLE 1
Baseline characteristics of the four treatment groups at the time of enrollment*
Characteristics Chloroquine SP SP + chloroquine SP + paracetamol
No. of patients 56 41 40 38
Age (months), mean (range) 28.8 (12–57) 29.3 (13–50) 26.7 (12–52) 25.6 (12–52)
Sex (male/female) 29/27 21/20 18/22 27/11
Hemoglobin (g/L), mean (range) 90 (59–129) 93 (55–131) 88 (56–123) 86 (53–123)
Baseline temperature (°C), mean (range) 38.5 (37.4–40.0) 38.5 (37.6–40.2) 38.5 (37.6–40.1) 38.3 (37.4–40.0)
Parasitemia (parasites/L), median (range) 24,880 (2,600–189,560) 42,240 (3,040–212,640) 52,200 (2,160–189,600) 56,620 (4,160–184,960)
* SP  sulfadoxine/pyrimethamine.
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chloroquine resistance in this part of Tanzania. This is in
agreement with other in vivo studies in different parts of this
country.17,18 In contrast, the occurrence of only one early
treatment failure by day 3 (< 1%) in the SP-treated children
suggests a relatively low degree of resistance to SP. The high
frequency of treatment failures to SP reported from the
Tanga region does not seem to have spread to the Kibaha
district.15,19
The addition of chloroquine to SP did not improve the
parasite clearance of SP alone. This is in agreement with pre-
vious studies,4,5 although clearance at day 28 turned out to be
improved for the combination in one of the studies.5 The
addition of paracetamol did not negatively affect parasite
clearance as was observed in a previous study.13 In our study,
the reduction of parasite densities during the first 24 hours
was most profound in the SP plus paracetamol-treated chil-
dren. Therefore, we do not believe that paracetamol itself or
fever reduction as such should negatively affect the clearance
of parasitemia.
The assumed antipyretic effect of chloroquine was con-
firmed because the addition of chloroquine to SP did not
improve parasite clearance, but significantly improved fever
clearance. Similarly, chloroquine also provided an antipyretic
effect comparable to what was achieved with paracetamol. A
tendency of increased temperature before the daily chloro-
quine dosing suggested that the antipyretic effect in both
chloroquine-treated groups lasted for less than 24 hours, de-
spite the relatively long early elimination half-life of the drug
(approximately 48 hours).20 However, the pattern of the fever
curve is strikingly similar to what was recorded for quinine-
treated children.21 The time points for low and peak values
also correspond with the normal endogenous circadian
rhythm (lowest point at approximately 6:00 AM and a peak at
approximately 6:00 PM).22,23 The different pattern detected in
the SP alone-treated children implies that this rhythm is dis-
turbed during acute uncomplicated P. falciparum malaria
treated without antipyretics, and that the antipyretic effect of
chloroquine (and possibly quinine) is influenced by what
drives the natural 24-hour rhythm.
TABLE 2




Chloroquine 37.4 37.1 37.3
SP 38.1 37.3 37.7
SP + chloroquine 37.1 36.6 36.9
SP + paracetamol 37.2 36.8 37.0
* SP  sulfadoxine/pyrimethamine.
TABLE 3
Number of patients positive for Plasmodium falciparum parasites
after 48 and 72 hours of treatment*
48 hours 72 hours
No. % No. %
Chloroquine 47/56 84 27/51 53
SP 13/41 32 5/41 12
SP + chloroquine 18/40 45 6/39 15
SP + paracetamol 17/38 45 4/38 11
Total 95/175 54 42/169 25
* SP  sulfadoxine/pyrimethamine.
FIGURE 1. Mean axillary temperature in four groups of patients with uncomplicated Plasmodium falciparum malaria. Children in the groups
treated with chloroquine alone, sulfadoxine/pyrimethamine (SP) alone, or chloroquine in combination with SP did not receive any antipyretic
drugs. Treatment started at 3:00−4:00 PM.
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Some degree of parasite clearance appeared to be required
for the antipyretic effect of chloroquine to be significant, since
children treated with chloroquine alone had more fever dur-
ing the second day compared with those treated with SP plus
chloroquine, who had more significant parasite recovery. Fur-
thermore, this was also supported by an association between
the reduction in fever and the reduction in parasitemia. The
antipyretic effect of chloroquine was weak or negligible in
most of the few children with early treatment failure. A
greater number of observations would be needed for this to
be proved. The relatively slow fever recovery effect by SP
treatment alone confirms previous similar preliminary find-
ings.3 However, the anti-parasitic effect brings about a reduc-
tion of fever during the second day, but an antipyretic drug is
still required up to 48 hours if clearance of fever is to be
achieved.
There was a general increase in IgG levels to P. falciparum
IgG during treatment, indicating ongoing humoral immune
responses during acute infection. No difference in this anti-
body response could be found between the groups, suggesting
that chloroquine does not appear to influence the humoral
immune response despite its anti-inflammatory properties.
This supports previous findings that chloroquine prophylaxis
does not influence the serologic response to non-live vac-
cines.24
In conclusion, if effective fever clearance is to be achieved,
chloroquine, possibly not a full standard anti-malarial treat-
ment dose, or an antipyretic such as paracetamol is necessary
as ancillary treatment to SP. The use of these drugs as anti-
pyretics does not seem to interfere with the parasite clearance
of SP.
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FIGURE 2. Parasite densities (medians and distributions) in chil-
dren with uncomplicated Plasmodium falciparum malaria after four
different treatment regimens. Blood smears were collected each day
at 3:00−4:00 PM before drug administration. h  hours; CQ  chlo-
roquine; SP  sulfadoxine/pyrimethamine; PA  paracetamol.
FIGURE 3. Association between changes in temperature and para-
site load between 0 and 48 hours for patients with uncomplicated
Plasmodium falciparum malaria treated with chloroquine alone
FIGURE 4. Median IgG levels in patients during treatment of un-
complicated Plasmodium falciparum malaria with four different drug
regimens. SP  sulfadoxine/pyrimethamine. Twenty-two patients
were treated with chloroquine alone, 24 with SP alone, 25 with chlo-
roquine plus SP, and 21 with SP plus paracetamol.
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